Association of the Polygenic Risk Score with the Incidence Risk of Parkinson’s Disease and Cerebrospinal Fluid α-Synuclein in a Chinese Cohort
Parkinson’s disease (PD) is attributed to interactions among genes and environmental and lifestyle factors, but the genetic architecture of PD is complex and not completely understood. To evaluate whether the genetic profile modifies PD development and cerebrospinal fluid (CSF) pathological biomarkers, we enrolled 418 PD patients and 426 age- and sex-matched normal controls. Forty-six single nucleotide polymorphisms (SNPs) that were reported to be significantly associated with PD in large-scale genome-wide association studies (GWASs) were genotyped and analysed. The alleles associated with PD were used to build polygenic risk score (PRS) models to represent polygenic risk. The Cox proportional hazards model and receiver operating characteristic (ROC) analyses were used to evaluate the prediction value of the PRS for PD risk and age at onset. The CSF α-synuclein levels were measured in a subgroup of control subjects (n = 262), and its relationship with the PRS was analysed. We found that some SNPs identified from other populations had significant correlations with PD in our Chinese cohort. The PRS we built had prediction value for PD risk and age at onset. The CSF α-synuclein level had no correlation with the PRS in normal subjects.
KeywordsParkinson’s disease Single nucleotide polymorphisms Polygenic risk score CSF biomarker α-Synuclein
This work was supported by the Chinese Ministry of Science and Technology (grant no. 2016YFC1306401).
Compliance with Ethical Standards
This study was approved by the Institutional Review Board of Daping Hospital, and all subjects and their caregivers provided informed consent.
The authors declare that they have no competing interests.
- Bu XL, Wang X, Xiang Y, Shen LL, Wang QH, Liu YH, Jiao SS, Wang YR, Cao HY, Yi X, Liu CH, Deng B, Yao XQ, Xu ZQ, Zhou HD, Wang YJ (2015) The association between infectious burden and Parkinson’s disease: a case-control study. Parkinsonism Relat Disord 21:877–881. https://doi.org/10.1016/j.parkreldis.2015.05.015 CrossRefGoogle Scholar
- Chang XL, Mao XY, Li HH, Zhang JH, Li NN, Burgunder JM, Peng R, Tan EK (2011) Association of GWAS loci with PD in China American journal of medical genetics part B, neuropsychiatric genetics : the official publication of the international society of. Psychiatr Genet 156B:334–339. https://doi.org/10.1002/ajmg.b.31167 Google Scholar
- Chen CM, Chen YC, Chiang MC, Fung HC, Chang KH, Lee-Chen GJ, Wu YR (2016) Association of GCH1 and MIR4697, but not SIPA1L2 and VPS13C polymorphisms, with Parkinson’s disease in Taiwan. Neurobiol Aging 39:221.e221–221.e225. https://doi.org/10.1016/j.neurobiolaging.2015.12.016 CrossRefGoogle Scholar
- Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L (2014) Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci 125:645–654. https://doi.org/10.3109/00207454.2014.961454 CrossRefGoogle Scholar
- Guo JF, Li K, Yu RL, Sun QY, Wang L, Yao LY, Hu YC, Lv ZY, Luo LZ, Shen L, Jiang H, Yan XX, Pan Q, Xia K, Tang BS (2015) Polygenic determinants of Parkinson’s disease in a Chinese population. Neurobiol Aging 36:1765 e1761–1765 e1766. https://doi.org/10.1016/j.neurobiolaging.2014.12.030 Google Scholar
- Ibanez L, Dube U, Saef B, Budde J, Black K, Medvedeva A, del-Aguila JL, Davis AA, Perlmutter JS, Harari O, Benitez BA, Cruchaga C (2017) Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurol 17:198. https://doi.org/10.1186/s12883-017-0978-z CrossRefGoogle Scholar
- Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C et al (2013) Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70:1277–1287. https://doi.org/10.1001/jamaneurol.2013.3861 Google Scholar
- Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simon-Sanchez J, Mittag F, Buchel F, Sharma M, Gibbs JR, Schulte C, Moskvina V, Durr A, Holmans P, Kilarski LL, Guerreiro R, Hernandez DG, Brice A, Ylikotila P, Stefansson H, Majamaa K, Morris HR, Williams N, Gasser T, Heutink P, Wood NW, Hardy J, Martinez M, Singleton AB, Nalls MA, for the International Parkinson's Disease Genomics Consortium (IPDGC) and The Wellcome Trust Case Control Consortium 2 (WTCCC2) (2013) Using genome-wide complex trait analysis to quantify ‘missing heritability’ in Parkinson’s disease. Hum Mol Genet 22:1696–1696. https://doi.org/10.1093/hmg/ddt030 CrossRefGoogle Scholar
- LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH et al (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145–154. https://doi.org/10.1016/s1474-4422(18)30405-8 CrossRefGoogle Scholar
- Liguori C, Paoletti FP, Placidi F, Ruffini R, Sancesario GM, Eusebi P, Mercuri NB, Parnetti L (2019) CSF biomarkers for early diagnosis of synucleinopathies: focus on idiopathic RBD. Curr Neurol Neurosci Rep 19. https://doi.org/10.1007/s11910-019-0918-y
- Liu ZH, Guo JF, Li K, Wang YQ, Kang JF, Wei Y, Sun QY, Xu Q, Wang DL, Xia K, Yan XX, Xu CS, Tang BS (2015) Analysis of several loci from genome-wide association studies in Parkinson’s disease in mainland China. Neurosci Lett 587:68–71. https://doi.org/10.1016/j.neulet.2014.12.027 CrossRefGoogle Scholar
- Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649. https://doi.org/10.1016/s0140-6736(10)62345-8 CrossRefGoogle Scholar
- Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41:1303–1307. https://doi.org/10.1038/ng.485 CrossRefGoogle Scholar
- Shulman JM, De Jager PL, Feany MB (2011) Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222. https://doi.org/10.1146/annurev-pathol-011110-130242 CrossRefGoogle Scholar
- Wu HC, Chen CM, Chen YC, Fung HC, Chang KH, Wu YR (2018) DLG2, but not TMEM229B, GPNMB, and ITGA8 polymorphism, is associated with Parkinson’s disease in a Taiwanese population. Neurobiol Aging 64:158.e151–158.e156. https://doi.org/10.1016/j.neurobiolaging.2017.11.016 CrossRefGoogle Scholar
- Zeng F, Shen C, Liu YH, Li J, Zhu J, Wang YR, Yan JC, Gao CY, Zhou HD, Deng J, Wang YJ (2015) Genetic association between APP, ADAM10 gene polymorphism, and sporadic Alzheimer’s disease in the Chinese population. Neurotox Res 27:284–291. https://doi.org/10.1007/s12640-015-9516-1 CrossRefGoogle Scholar
- Zou M, Li R, Wang JY, Wang K, Wang YN, Li Y, Ji FX, Sun SN, Huang SS, Fan HH, Huang CP, Zhang X, Zhu JH (2018) Association analyses of variants of SIPA1L2, MIR4697, GCH1, VPS13C, and DDRGK1 with Parkinson’s disease in East Asians. Neurobiol Aging 68:159.e157–159.e114. https://doi.org/10.1016/j.neurobiolaging.2018.03.005 CrossRefGoogle Scholar